Early Phase 1 N=12 Evaluation of Bioavailability of Diclofenac Dermal Products
Bioavailability
Primary: Serum Diclofenac Concentrations — 5.6; 40.0 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=152 Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Social Anxiety Symptom Severity — -.46; -.90; -.39; -.88 score on a scale — p=<.001
Early Phase 1 N=38 Feasibility and Outcomes of a Digital Health Support for the Schizophrenia Spectrum
Schizophrenia Spectrum and Other Psychotic Disorders
Primary: Symptomatology — 41.66; 4.34; 4.29; 4.29 score on a scale — p=0.067
Early Phase 1 N=12 Pressure Assessment to Improve Outcomes After TAVR: a Registry
Hypertension · Aortic Stenosis, Calcific · Quality of Life
Primary: Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Summary Score — 59.4; 74.1 score on a scale — p=0.12
Early Phase 1 N=70 Comparison of Chloroprocaine vs Lidocaine for Epidural Anesthesia in Cesarean Delivery
Surgical Anesthesia, Cesarean Section
Primary: The Onset Time to Surgical Anesthesia — 558; 655 seconds — p=0.10
Early Phase 1 N=36 A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
Breast Cancer Female
Primary: Identifying Molecular Alterations in Breast Cancer Tissue Tumor Samples Following Short-Term Preoperative Exposure to Darolutamide in Female Patients Wit Early Breast…
Early Phase 1 N=42 Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women
Pertussis · Pregnancy Related
Primary: The Seroprevalence of Anti-pertussis Toxin Antibodies (Anti-PT IgG) in Pregnant Thai Women — 43 Participants
Early Phase 1 N=3 Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
Sexual Dysfunction · Sexual Arousal Disorder · Sexual Dysfunction, Physiological
Primary: Change in Delayed Orgasm Grade — -0.33 Grade
Early Phase 1 N=30 Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Breast Cancer
Primary: Clinical Response Rate (cRR) — 6; 18; 5; 0 participants
Early Phase 1 N=106 Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome
Polycystic Ovarian Syndrome
Primary: Cytokines and Chemokines Measurements — 14.60; 14.12; 12.65; 11.12 pg/ml
Early Phase 1 N=103 Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Cervical Cancer · Uterine Endometrial Cancer · Ovarian Cancer
Primary: Hospital Stay — 3.0; 3.0 Days — p=0.36
Early Phase 1 N=13 Probiotics for Quality of Life in Autism Spectrum Disorders
Autism Spectrum Disorders · Anxiety
Primary: Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) at From Baseline at Week 8 — 17.97; 7.98 Units on a scale
Early Phase 1 N=15 Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes
Type 1 Diabetes
Primary: Peak Post-prandial Venous Glucose Levels — 98; 76 mg/dL — p=0.05
Early Phase 1 N=143 Emergence Agitation and Pain Scores in Pediatrics When Comparing Single-modal vs Multi-modal Analgesia for ENT Surgery
Emergence Agitation · Pain
Primary: Emergence Agitation (EA) as Measured by Standardized PAED Scale — 5.3; 4.99; 6.29 score on a scale
Early Phase 1 N=18 Safety and Pharmacokinetics of an Extract of Naringenin
Safety Issues · Pharmacokinetics
Primary: Incidence of Treatment-emergent Adverse Events Following a Single Dose of a Citrus Extract of Naringenin — 1; 2; 0; 1 Participants